Fulgent Genetics, Inc
4978 Santa Anita Avenue
Suite 205
Temple City
California
91780
United States
Tel: 626-350-0537
Fax: 626-454-1667
Website: https://www.fulgentgenetics.com/
Email: info@fulgentgenetics.com
About Fulgent Genetics, Inc
Founded in 2011, Fulgent began with two simple ideas; flexibility and affordability. Today, we strive to create the most effective and wide ranging tests on the market. All of this is done in the pursuit of bettering the everyday lives of our customers. We shine brightest when meaningful relationships, passion, and purpose come together.YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Ming Hsieh
CSO: Hanlin Gao
JOBS:
Please click here for Fulgent job opportunities.
FOLLOW FULGENT DIAGNOSTICS:
Tweets by Fulgent Diagnostics
96 articles about Fulgent Genetics, Inc
-
Fulgent Genetics Reports Third Quarter 2022 Financial Results
11/7/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its third quarter ended September 30, 2022.
-
Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
11/7/2022
Fulgent Genetics, Inc. announced that it has completed an acquisition of Fulgent Pharma Holdings, Inc., an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments.
-
Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference
10/25/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to participate in Credit Suisse’s 31st Annual Healthcare Conference on Tuesday, November 8, 2022.
-
Fulgent Genetics to Announce Third Quarter 2022 Financial Results on Monday November 7, 2022
10/20/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its third quarter 2022 financial results after the market closes on Monday November 7, 2022.
-
Fulgent Genetics Reports Second Quarter 2022 Financial Results
8/4/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022.
-
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
8/4/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of two therapeutic industry veterans to its board of directors.
-
Fulgent Genetics Announces Launch of PCR Based Test to Detect Monkeypox
8/4/2022
Fulgent Genetics, Inc. today announced it has launched a test for monkeypox that leverages the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test.
-
Fulgent Genetics to Announce Second Quarter 2022 Financial Results on Thursday, August 4, 2022
7/19/2022
Fulgent Genetics, Inc. today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022.
-
The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test
7/5/2022
Helio Genomics, and its commercial partner, Fulgent Genetics announced that the American Medical Association has issued a new Category I Current Procedural Terminology Proprietary Laboratory Analyses code for HelioLiver™, enabling a reimbursement pathway for potential increased access and broader adoption of innovative surveillance tests for liver cancer in the U.S. The code will become effective on October 1, 2022.
-
Fulgent Genetics Reports First Quarter 2022 Financial Results
5/3/2022
Fulgent Genetics, Inc., a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced financial results for its first quarter ended March 31, 2022.
-
Fulgent Genetics Announces Promotions and Leadership Updates
5/3/2022
Fulgent Genetics, Inc., a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced a number of promotions and appointments across its leadership team.
-
Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results
4/18/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced today that it has entered into a definitive agreement to acquire Inform Diagnostics, a leading national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners.
-
Fulgent Genetics to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022
4/18/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its first quarter 2022 financial results after the market closes on Tuesday, May 3, 2022.
-
Representatives of Fulgent Genetics to Participate in Oppenheimer’s 32nd Annual Healthcare Conference
3/8/2022
Fulgent Genetics, Inc. announced that members of its management team are scheduled to virtually participate in Oppenheimer’s 32nd Annual Healthcare Conference on Tuesday, March 15, 2022.
-
Fulgent Genetics Announces $250 Million Share Repurchase Program
3/8/2022
Fulgent Genetics, Inc. announced that its Board of Directors has authorized a share repurchase program under which Fulgent may repurchase up to $250 million in shares of its common stock.
-
EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS
2/24/2022
Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients.
-
Fulgent Genetics Announces Strategic Investment in Spatial Genomics
2/23/2022
Fulgent Genetics, Inc. today announced a strategic investment in Spatial Genomics, Inc.
-
Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results
2/23/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021.
-
Fulgent Genetics to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday February 23, 2022
2/14/2022
Fulgent Genetics, Inc. today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Wednesday February 23, 2022.
-
HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available
12/6/2021
Helio Health (“Helio”) and its commercial partner, Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), today announced the commercial launch of HelioLiver™ , a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer.